Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
NCT03057600
Completed
CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in participants of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839 will be administered in combination with the full approved dose of paclitaxel.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/19/2022
Locations: University of Alabama at Brimingham, Birmingham, Alabama +24 locations
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Register for Updates
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
NCT03085914
Completed
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as Treatment Groups A through G below (see Study Drug and Background Therapies, Dose, and Mode of Administration). Phase 1 consisted of a 3 + 3 + 3 design intended to determine the MTD or PAD of epacadostat when given in combination with pembrolizumab and chemotherapy; effica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2022
Locations: Mayo Clinic Arizona, Phoenix, Arizona +15 locations
Conditions: Solid Tumor
Register for Updates
Folfox+Irinotecan+Chemort In Esophageal Cancer
NCT04656041
Recruiting
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: - Liposomal irinotecan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Register for Updates
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
NCT05190445
Active Not Recruiting
A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Sansum Clinic, Santa Barbara, California +4 locations
Conditions: HER2-positive Gastric Cancer
Register for Updates
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
NCT03279237
Unknown
This research study is studying a combination of interventions as a possible treatment for gastroesophageal (GE) junction cancer. The interventions involved in this study are: -FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Paclitaxel * Carboplatin * Proton Beam Radiation Therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: GastroEsophageal Cancer
Register for Updates
Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
NCT02588443
Completed
The main purpose of this study is to learn if adding the investigational drug RO7009789 (anti-CD40) to nab-paclitaxel and gemcitabine both before surgery and after surgery is safe, feasible, and beneficial to patients with pancreatic cancer. This study also intends to look at blood and tissue samples to help doctors better understand the role of the immune system in fighting cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2022
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreatic Cancer
Register for Updates
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
NCT03056833
Completed
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/01/2022
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan +7 locations
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Register for Updates
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
NCT01113476
Completed
The goal of this clinical research study is to find the highest tolerable dose of the combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab) that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Register for Updates
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT02394535
Completed
This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with capecitabine and radiation therapy following first treatment with chemotherapy (induction therapy) in treating patients with pancreatic cancer that is not spread to tissue far away but is not operable due to abutment or encasement of blood vessels nearby (locally advanced). Drugs used in chemotherapy, such as nab-paclitaxel and capecitabine, work in different ways to stop the growth of tumor cell... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/31/2022
Locations: M D Anderson Cancer Center, Houston, Texas +4 locations
Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7
Register for Updates
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00373217
Terminated
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor ce... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/25/2022
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
NCT02370238
Completed
The Objectives of this study: The primary objective of the study was to evaluate progression-free survival (PFS) (defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, as assessed by Independent Radiology Review, or death for any cause, whichever occured first) in patients with metastatic triple-negative breast cancer (TNBC) treated with the combin... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/23/2022
Locations: Southern Cancer Center, Mobile, Alabama +76 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
NCT03894540
Terminated
The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates